New research reveals that individuals who stop using blockbuster weight-loss injections like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who halt conventional diet and exercise plans.
Published data in a leading medical journal points out that while obese people often shed substantial amounts of their total mass while using the jabs, the mass is regained at an estimated rate of nearly a kilo each month after stopping.
"People using such medications need to be cognizant of the potential of fast rebound weight gain when the treatment ends," warns researcher Dr. Susan Jebb.
This pace of recovery implies a reversion to pre-treatment mass in about a year and a half.
Comparing Approaches
The study, which reviewed 37 of trials involving thousands of participants, contrasted the results of GLP-1 agonists with other pills.
Scientists point out that people who lose weight through lifestyle changes alone usually experience a more gradual creep back—approximately 0.1 kg a month—once they finish.
Explaining the Rapid Regain
Experts propose the way of the drugs accounts for the heightened regain.
The injections mimic a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Artificially providing GLP-1 levels several times higher than the body's typical production might result in the body to generate a reduced amount of its own natural hormone, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' means appetite is no longer kept in check, making excessive eating a significant risk."
An Ongoing Disease?
Health authorities advise the injections for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Professionals argue that, considering the high risk of relapse, the treatment is often ongoing.
This perspective is reinforced by pharmaceutical companies, who note that the findings "highlight the chronic nature of excess weight," comparing it to managing conditions like diabetes.
Patient Experiences
People who have come off the jabs describe a powerful return of hunger.
"I experienced a trigger flipping and you become starving," recalled a patient.
The struggle is exacerbated if patients have not established permanent dietary or behavioural changes during therapy.
Significant Interest
Figures show that a significant number of adults in the UK have tried these injections in the last 12 months, with interest being substantial.
- Adoption is greater among females than men.
- The middle-aged age group shows the greatest usage rates.
- Many obtain the drugs through private prescriptions rather than the NHS.
In conclusion, researchers emphasize that while these medications are potent tools for weight loss, they are not a permanent solution and long-term success relies on combined behavioural support.
